|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28 (Suppl
1):S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neville-Webbe HL and Coleman RE:
Bisphosphonates and RANK ligand inhibitors for the treatment and
prevention of metastatic bone disease. Eur J Cancer. 46:1211–1222.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Salvatore M, Orlandi A, Bagalà C,
Quirino M, Cassano A, Astone A and Barone C: Anti-tumour and
anti-angiogenetic effects of zoledronic acid on human
non-small-cell lung cancer cell line. Cell Prolif. 44:139–146.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morgan G and Lipton A: Antitumour effects
and anticancer applications of bisphosphonates. Semin Oncol. 37
(Suppl 2):S30–S40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng C, Liu X, Li X, Guo F, Huang C, Qin Q
and Wang Y: Zoledronic acid increases the antitumour effect of
gefitinib treatment for non-small cell lung cancer with EGFR
mutations. Oncol Rep. 35:3460–3470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang CY, Wang L, Feng CJ, Yu P, Cai XH,
Yao WX, Xu Y, Liu XK, Zhu WJ, Wang Y, et al: Bisphosphonates
enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR
activating mutation: A retrospective study. Oncotarget.
7:664802016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang G, Cheng R, Zhang Z, Jiang T, Ren S,
Ma Z, Zhao S, Zhou C and Zhang J: Bisphosphonates enhance
antitumour effect of EGFR-TKIs in patients with advanced EGFR
mutant NSCLC and bone metastases. Sci Rep. 7:429792017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen L, Huang C, Yang X, Zhang Q and Chen
F: Prognostic roles of mRNA expression of peroxiredoxins in lung
cancer. Onco Targets Ther. 11:8381–8388. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shih JY, Gow CH and Yang PC: EGFR mutation
conferring primary resistance to gefitinib in non-small-cell lung
cancer. N Engl J Med. 353:207–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kosaka T, Yatabe Y, Endoh H, Yoshida K,
Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer and acquired resistance to gefitinib.
Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cohen S, Bruchim I, Graiver D, Evron Z,
Oron-Karni V, Pasmanik-Chor M, Eitan R, Bernheim J, Levavi H,
Fishman A and Flescher E: Platinum-resistance in ovarian cancer
cells is mediated by IL-6 secretion via the increased expression of
its target cIAP-2. J Mol Med (Berl). 91:357–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nilsson MB, Langley RR and Fidler IJ:
Interleukin-6, secreted by human ovarian carcinoma cells, is a
potent proangiogenic cytokine. Cancer Res. 65:10794–10800. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Middleton K, Jones J, Lwin Z and Coward
JI: Interleukin-6: An angiogenic target in solid tumours. Crit Rev
Oncol Hematol. 89:129–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bharti R, Dey G and Mandal M: Cancer
development, chemoresistance, epithelial to mesenchymal transition
and stem cells: A snapshot of IL-6 mediated involvement. Cancer
Lett. 375:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Derenne S, Amiot M, Barillé S, Collette M,
Robillard N, Berthaud P, Harousseau JL and Bataille R: Zoledronate
is a potent inhibitor of myeloma cell growth and secretion of IL-6
and MMP-1 by the tumoural environment. J Bone Miner Res.
14:2048–2056. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gallo M, De Luca A, Lamura L and Normanno
N: Zoledronic acid blocks the interaction between mesenchymal stem
cells and breast cancer cells: Implications for adjuvant therapy of
breast cancer. Ann Oncol. 23:597–604. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Asbagh LA, Uzunoglu S and Cal C:
Zoledronic acid effects interleukin-6 expression in
hormone-independent prostate cancer cell lines. Int Braz J Urol.
34:355–363; discussion 364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishibashi K, Haber T, Breuksch I, Gebhard
S, Sugino T, Kubo H, Hata J, Koguchi T, Yabe M, Kataoka M, et al:
Overriding TKI resistance of renal cell carcinoma by combination
therapy with IL-6 receptor blockade. Oncotarget. 8:55230–55245.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scott HR, McMillan DC, Crilly A, McArdle
CS and Milroy R: The relationship between weight loss and
interleukin 6 in non-small-cell lung cancer. Br J Cancer.
73:1560–1562. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg
JF: Mutations in the EGFR kinase domain mediate STAT3 activation
via IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Che Q, Liu BY, Wang FY, He YY, Lu W, Liao
Y, Gu W and Wan XP: Interleukin 6 promotes endometrial cancer
growth through an autocrine feedback loop involving ERK-NF-κB
signaling pathway. Biochem Biophys Res Commun. 446:167–172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumour specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Uramoto H, Iwata T, Onitsuka T, Shimokawa
H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in
EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res.
30:2513–2517. 2010.PubMed/NCBI
|
|
34
|
Byers LA, Diao L, Wang J, Saintigny P,
Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An
epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a
therapeutic target for overcoming EGFR inhibitor resistance. Clin
Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Davis FM, Stewart TA, Thompson EW and
Monteith GR: Targeting EMT in cancer: Opportunities for
pharmacological intervention. Trends Pharmacol Sci. 35:479–488.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marcucci F, Stassi G and De Maria R:
Epithelial-mesenchymal transition: A new target in anticancer drug
discovery. Nat Rev Drug Discov. 15:311–325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chung JH, Rho JK, Xu X, Lee JS, Yoon HI,
Lee CT, Choi YJ, Kim HR, Kim CH and Lee JC: Clinical and molecular
evidences of epithelial to mesenchymal transition in acquired
resistance to EGFR-TKIs. Lung Cancer. 73:176–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
